Iksuda Therapeutics announces first patient successfully dosed in phase 1 trial evaluating IKS03 in advanced B cell non-Hodgkin lymphomasContributed by: Business WireTagsScienceOther ScienceBiotechnologyResearchPharmaceuticalOncologyHealthFDAIKS03